First I have shared it, but I think $8 is realistic this time next year.
Look at the implied margin of safety against a potentially large buyout value, this based on the AMGEN buyout of Micromet ( and that was just for ALL which is less than 1/3rd the number of annual cases, and excluding Breast Cancer ).
In July 2021 could be within about 2 months of a Breast Cancer readout and within 4 months of another AML readout ... and we know how successful the historic trials were.
Buyout deals for promising cancer treatments can easily achieve over USD $6B. RAC's Bisantrene has promise for high revenue potential.
RAC Price at posting:
76.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)